Marker Therapeutics, Inc.

Category: Press Releases

Marker Therapeutics Provides Updates of its Lead Clinical Programs

The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.
Read More

Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit

President and CEO, Peter L. Hoang, will be participating at the Tumor Targeted Lymphocyte Summit.
Read More

The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting

Data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018).
Read More

Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer

“Over my career, I’ve had the chance to work with many great companies, a number of which have had a major impact within the biotech sector that led to great advances in patient care. However, I believe Marker Therapeutics’ patient data are truly exceptional, generating excellent complete response rates in a meaningful number of patients to date. ," said Mr. Kim.
Read More

Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

President and CEO, Peter L. Hoang, will be participating in several healthcare conferences this month.
Read More

Marker Therapeutics, Inc. Announces New Executive Appointments

"We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.
Read More

Marker to Present at Two Upcoming Cellular Therapy Conferences

Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.
Read More

TapImmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing

“The closing of this merger marks a significant milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially transformative therapies,” said Peter Hoang, CEO of Marker Therapeutics, Inc. Learn more about Marker Therapeutics, Inc. by going to www.markertherapeutics.com
Read More

TapImmune’s HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination Study Funded by an $11 Million U.S. Department of Defense Grant

Peter L. Hoang, President and CEO of TapImmune, stated, “I am delighted that the U.S. Department of Defense has again chosen to support our technology and therapeutic platform with another funding commitment.
Read More

TapImmune to Present at Two Upcoming Investor Conferences

Peter L. Hoang will be presenting at the 2018 Cantor Global Healthcare Conference and the Sachs Associates 18th Annual Biotech in Europe Forum. Webcast will be available for both events.
Read More